BridgeBio Oncology Therapeutics's total assets for Q1 2026 were $417.65M, a decrease of -6.85% from the previous quarter. BBOT total liabilities were $45.37M for the fiscal quarter, a 21.67% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.